Evidence map›Paper›PMID 28988014›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2017

L-Asparaginase of Leishmania donovani: Metabolic target and its role in Amphotericin B resistance.

Jasdeep Singh, Mohd Imran Khan, Shiv Pratap Singh Yadav, Ankit Srivastava, Kislay K Sinha, Ashish, Pradeep Das, Bishwajit Kundu

Open access · goldAbstract read
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Identification ofACS omega · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jasdeep SinghKusuma School of Biological Sciences, Indian Institute of Technology Delhi, New Delhi 110016, India.
Mohd Imran KhanNational Institute of Pharmaceutical Education & Research, EPIP Complex, Hajipur, Vaishali 844102, India.
Shiv Pratap Singh YadavThe Council of Scientific and Industrial Research Institute of Microbial Technology, Chandigarh, India.
Ankit SrivastavaKusuma School of Biological Sciences, Indian Institute of Technology Delhi, New Delhi 110016, India.
Kislay K SinhaNational Institute of Pharmaceutical Education & Research, EPIP Complex, Hajipur, Vaishali 844102, India.
AshishThe Council of Scientific and Industrial Research Institute of Microbial Technology, Chandigarh, India.
Pradeep DasRajendra Memorial Research Institute of Medical Sciences, Patna 800007, India.
Bishwajit KunduKusuma School of Biological Sciences, Indian Institute of Technology Delhi, New Delhi 110016, India. Electronic address: bkundu@bioschool.iitd.ac.in.
Indian Institute of Technology Delhi · INInstitute of Microbial Technology · INNational Institute of Pharmaceutical Education and Research · INRajendra Memorial Research Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emergence of Amphotericin B (AmB) resistant Leishmania donovani has posed major therapeutic challenge against the parasite. Consequently, combination therapy aimed at multiple molecular targets, based on proteome wise network analysis has been recommended. In this regard we had earlier identified and proposed L-asparaginase of Leishmania donovani (LdAI) as a crucial metabolic target. Here we report that both LdAI overexpressing axenic amastigote and promastigote forms of L. donovani survives better when challenged with AmB as compared to wild type strain. Conversely, qRT-PCR analysis showed an upregulation of LdAI in both forms upon AmB treatment. Our data demonstrates the importance of LdAI in imparting immediate protective response to the parasite upon AmB treatment. In the absence of structural and functional information, we modeled LdAI and validated its solution structure through small angle X-ray scattering (SAXS) analysis. We identified its specific inhibitors through ligand and structure-based approach and characterized their effects on enzymatic properties (K

Indexed as

Amphotericin BAntiprotozoal AgentsAsparaginaseDrug ResistanceInhibitory Concentration 50KineticsLeishmania donovaniLeishmaniasis, VisceralMetabolic Networks and PathwaysModels, MolecularProtozoan ProteinsReal-Time Polymerase Chain ReactionScattering, Small AngleX-Ray DiffractionAmphotericin BAntiprotozoal AgentsAsparaginaseProtozoan ProteinsAmphotericin B resistanceL-asparaginaseLeishmania donovaniMetabolic target

Identifiers

PMID28988014
PMCPMC5633258
OpenAlexW2760263479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.